Aref Al-Kali, MD of Mayo Clinic discusses the approval of midostaurin for FLT3+ AML patients. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.
How quickly do you think hematologists will adopt the recently approved midostaurin for FLT3+ AML patients
